Lampiran 3 OUTPUT DATA HASIL PENELITIAN
a. Hasil Uji Deskriptif Usia, Jenis IMT, dan Kelompok PSA
Kelompok Usia
Frequency Percent
Valid Percent Cumulative
Percent Valid
50 7
5.6 5.6
5.6 50-59
20 16.0
16.0 21.6
60-69 52
41.6 41.6
63.2 69
46 36.8
36.8 100.0
Total 125
100.0 100.0
IMTgroups
Frequency Percent
Valid Percent Cumulative
Percent Valid
Kurus 16
12.8 12.8
12.8 Normal
72 57.6
57.6 70.4
BBLebih 11
8.8 8.8
79.2 Obes
26 20.8
20.8 100.0
Total 125
100.0 100.0
Nilai Kadar PSA kelompok
Frequency Percent
Valid Percent Cumulative
Percent Valid
≤ 4 62
49.6 49.6
49.6 4
63 50.4
50.4 100.0
Total 125
100.0 100.0
Statistics
Usia IMT
PSA N
Valid 125
125 125
Missing Mean
66.02 23.22827
11.9880 Median
67.00 23.23400
4.1000 Mode
69 23.438
.60
Universitas Sumatera Utara
b. Hasil Uji Normalitas Nilai IMT dan Kadar Serum PSA
Tests of Normality
Kolmogorov-Smirnov
a
Shapiro-Wilk Statistic
df Sig.
Statistic df
Sig. IMT
.059 125
.200 .992
125 .696
PSA .289
125 .000
.546 125
.000 . This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Histogram
Universitas Sumatera Utara
c. Hasil Uji Korelasi Spearman
Correlations
IMT PSA
Spearmans rho IMT
Correlation Coefficient 1.000
-.368 Sig. 2-tailed
. .000
N 125
125 PSA
Correlation Coefficient -.368
1.000 Sig. 2-tailed
.000 .
N 125
125 . Correlation is significant at the 0.01 level 2-tailed.
Universitas Sumatera Utara
d. Hasil Uji Regresi Linier
Variables EnteredRemoved
a
Model Variables
Entered Variables
Removed Method
1 IMT
b
. Enter a. Dependent Variable: PSA
b. All requested variables entered.
Model Summary
Model R
R Square Adjusted R
Square Std. Error of the
Estimate 1
.353
a
.124 .117
19.92266 a. Predictors: Constant, IMT
ANOVA
a
Model Sum of Squares
df Mean Square
F Sig.
1 Regression
6939.382 1
6939.382 17.483
.000
b
Residual 48820.230
123 396.912
Total 55759.612
124 a. Dependent Variable: PSA
b. Predictors: Constant, IMT
Coefficients
a
Model Unstandardized Coefficients
Standardized Coefficients
t Sig.
B Std. Error
Beta 1
Constant 59.478
11.497 5.174
.000 IMT
-2.044 .489
-.353 -4.181
.000 a. Dependent Variable: PSA
Universitas Sumatera Utara
Grafik Linier
Universitas Sumatera Utara
Lampiran 4
Universitas Sumatera Utara
Lampiran 5
Universitas Sumatera Utara
Universitas Sumatera Utara
DAFTAR PUSTAKA
Arneth, Borros M., 2009. Clinical Significance of Measuring Prostate-specific Antigen. Labmedicine; 40 8: 487-491
AUA Commentary, 2000. Prostate-specific Antigen Best Practice Policy. Oncology; 142: 267.
Brawer MK, Kirby R, 1999. Prostate Specific Antigen ed. 2
nd
. Singapore: Health Press Limited
Chiang, Andrew S. et al, 2013. Utility of 5-Alpha-Reductase Inhibitors in Active Surveillance for Favourable Risk Prostate Cancer. Can Urol
Assoc J; 711-12: 450-4533
Chiu, Peter Ka-Fung et al., 2011. Effect of Body Mass Index on Serum Prostate-Specific Antigen Levels among Patients Presenting with
Lower Urinary Tract Symptoms. Asian Pacific Journal of Cancer Prevention; 12:1937-1940
Durmaz, Tahir et al., 2014. Is There a Relationship Between Acute Coronary Syndrome and Prostate Specific Antigen Level?. Urology Journal; 11
1: 1278-1286
Eknoyan, Garabed, 2008. Adolphe Quetelet 1796-1874: The Average Man and Indices of Obesity. Nephrol. Dial. Transplant; 23: 47–51
Erlangga N, Dimas, 2007. Ketepatan Diagnostik Prostat Spesifik Antigen pada Keganasan Prostat di Rumah Sakit Dokter Kariadi Semarang.
Semarang: Fakultas Kedokteran Universitas Diponegoro
Garrow JS, Webster J., 1985. Quatelet’s Index WH2 as A Measure of Fatness. Int. J. Obes. Related Metabolic Disord.; 9: 147-153
Ganesh, B. et al., 2011. Risk Factors for Prostate Cancer: An Hospital-Based Case-Control Study from Mumbai, India. Indian J Urol.; 273: 345–
350
Ikatan Ahli Urologi Indonesia, 2009. Pedoman Penatalaksanaan BPH di Indonesia.
Universitas Sumatera Utara
Ikatan Ahli Urologi Indonesia, 2011. Pedoman Penatalaksanaan Kanker Prostat.
Joseph E, Oesterling, 1991. Prostate Specific Antigen, a Crucial Assesment of the Most Useful Tumor Markers for Adenocarcinoma of the Prostate.
The Journal Of Urology; 145: 907-923.
K. O. H, William et al., 2000. Neoplasm of the Prostate. Dalam: C. Bast, Robert et al. Holland - Frei Cancer Medicine 5
th
ed.. USA : BC Decker Inc
Lee, Sang Hun et al, 2013. Impact of Treatment with Statins on Prostate- Specific Antigen and Prostate Volume in Patients with Benign Prostatic
Hyperplasia. Korean Journal of Urology; 54: 750-755
Lilja H. et al, 1991. Prostate-specific Antigen in Serum occurs Predominately in Complex with Α1-anticymptrypsin. Clin. Chem., 37: 1618-1625
Lionel L, Banez et al, 2007. Obesity-related Plasma Hemodilution and PSA Concentration among Men with Prostate Cancer. The Journal of the
American Medical Association; 298: 2275–2280.
Montironi R, Mazzucchelli R, Algaba F., 2000. Prostate-specific Antigen as a Marker of Prostate Disease. Virchows Arch.; 436: 297-304.
Muller, Heiko et al, 2009. Association of Diabetes and Body Mass Index with Levels of Prostate-specific Antigen: Implications for Correction of
Prostate-specific Antigen Cutoff Values. Cancer Epidemiol Biomarkers Prev; 18: 1350-1356
Partin, Alan W.. et al. 2012. Campbell-Walsh Urology, Tenth Edition: Prostate. Amerika: Elsevier Saunders
Soegondo, Sidartawan Purnamasari, Dyah, 2006. Sindrom Metabolik. Dalam: Sudoyo, Aru W. dkk., 2009. Buku Ajar Ilmu Penyakit Dalam
jilid III ed. 5. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedikteran Universitas Indonesia
Tanagho, Emil A., McAninch, Jack W., 2008. Smith’s General Urology edisi 17: Anatomy of the Genitourinary Tract. San Francisco: The McGraw-
Hill Companies, Inc.
Universitas Sumatera Utara
WHO, 2000. Technical Report Series 894; Obesity; Preventing and Managing the Global Epidemic. Swiss: WHO
WHO. BMI Classification. Di akses pada: 26 Mei 2014. Dari: http:apps.who.intbmiindex.jsp?introPage=intro_3.html
Universitas Sumatera Utara
BAB 3 KERANGKA KONSEP DAN DEFINISI OPERASIONAL
3.1. Kerangka Konsep Penelitian
